Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2020 | Nov. 12, 2020 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2020 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q3 | |
Document Transition Report | false | |
Entity File Number | 000-22904 | |
Entity Registrant Name | PARKERVISION INC | |
Entity Central Index Key | 0000914139 | |
Entity Incorporation, State or Country Code | FL | |
Entity Tax Identification Number | 59-2971472 | |
Entity Address, Address Line One | 4446-1A Hendricks Avenue | |
Entity Address, Address Line Two | Suite 354 | |
Entity Address, City or Town | Jacksonville | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 32207 | |
City Area Code | 904 | |
Local Phone Number | 732-6100 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Emerging Growth Company | false | |
Entity Common Stock, Shares Outstanding | 52,878,723 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 147 | $ 57 |
Prepaid expenses | 660 | 505 |
Other current assets | 8 | 117 |
Total current assets | 815 | 679 |
Operating lease right-of-use assets | 11 | 283 |
Intangible assets, net | 2,326 | 2,878 |
Other assets, net | 68 | 86 |
Total assets | 3,220 | 3,926 |
CURRENT LIABILITIES: | ||
Accounts payable | 4,321 | 2,328 |
Accrued expenses: | ||
Salaries and wages | 39 | 78 |
Professional fees | 145 | 499 |
Statutory court costs | 237 | 369 |
Other accrued expenses | 549 | 1,081 |
Related party note payable, current portion | 99 | 86 |
Secured note payable, current portion | 25 | 1,222 |
Unsecured notes payable | 40 | 225 |
Operating lease liabilities, current portion | 183 | 250 |
Total current liabilities | 5,638 | 6,138 |
LONG-TERM LIABILITES: | ||
Secured contingent payment obligation | 28,788 | 26,651 |
Convertible notes, net | 3,010 | 2,733 |
Related party note payable, net of current portion | 726 | 793 |
Unsecured contingent payment obligations | 3,773 | |
Operating lease liabilities, net of current portion | 198 | 305 |
Other long-term liabilities | 154 | 403 |
Total long-term liabilities | 36,649 | 30,885 |
Total liabilities | 42,287 | 37,023 |
SHAREHOLDERS' DEFICIT: | ||
Common stock, $.01 par value, 140,000 and 110,000 shares authorized, 51,960 and 34,097 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively | 520 | 341 |
Additional paid-in capital | 375,370 | 368,345 |
Accumulated deficit | (414,957) | (401,783) |
Total shareholders' deficit | (39,067) | (33,097) |
Total liabilities and shareholders' deficit | $ 3,220 | $ 3,926 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Condensed Consolidated Balance Sheets [Abstract] | ||
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 140,000 | 110,000 |
Common stock, shares issued | 51,960 | 34,097 |
Common stock, shares outstanding | 51,960 | 34,097 |
Condensed Consolidated Statemen
Condensed Consolidated Statements Of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Condensed Consolidated Statements Of Comprehensive Loss [Abstract] | ||||
Product revenue | $ 35 | $ 70 | ||
Cost of sales | (35) | (70) | ||
Gross margin | ||||
Research and development expenses | 334 | |||
Selling, general and administrative expenses | 1,445 | 1,950 | $ 9,268 | 5,957 |
Total operating expenses | 1,445 | 1,950 | 9,268 | 6,291 |
Interest and other income | 1 | 3 | 1 | 3 |
Interest expense | (119) | (104) | (420) | (242) |
Change in fair value of contingent payment obligations | (105) | (68) | (3,487) | 755 |
Total interest and other | (223) | (169) | (3,906) | 516 |
Net loss | (1,668) | (2,119) | (13,174) | (5,775) |
Other comprehensive loss, net of tax | ||||
Comprehensive loss | $ (1,668) | $ (2,119) | $ (13,174) | $ (5,775) |
Basic and diluted net loss per common share | $ (0.03) | $ (0.07) | $ (0.29) | $ (0.19) |
Weighted average common shares outstanding | 50,530 | 32,012 | 44,772 | 30,706 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements Of Shareholders' Deficit - USD ($) $ in Thousands | Common Stock [Member]Long-term Debt [Member] | Common Stock [Member]Short-term Debt [Member] | Common Stock [Member] | Additional Paid-in Capital [Member]Long-term Debt [Member] | Additional Paid-in Capital [Member]Short-term Debt [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member]Long-term Debt [Member] | Accumulated Deficit [Member]Short-term Debt [Member] | Accumulated Deficit [Member] | Long-term Debt [Member] | Short-term Debt [Member] | Total |
Cumulative effect of change in accounting principle | $ (38) | $ (38) | ||||||||||
Balance, value at Dec. 31, 2018 | 287 | 366,695 | (392,292) | (25,310) | ||||||||
Issuance of common stock upon exercise of warrants | 15 | 15 | ||||||||||
Issuance of common stock upon conversion | $ 4 | $ 76 | $ 80 | |||||||||
Share-based compensation, net of shares withheld for taxes | 67 | 67 | ||||||||||
Comprehensive loss for the period | (2,094) | (2,094) | ||||||||||
Balance, value at Mar. 31, 2019 | 306 | 366,838 | (394,424) | (27,280) | ||||||||
Balance, value at Dec. 31, 2018 | 287 | 366,695 | (392,292) | (25,310) | ||||||||
Comprehensive loss for the period | (5,775) | |||||||||||
Balance, value at Sep. 30, 2019 | 335 | 368,050 | (398,105) | (29,720) | ||||||||
Balance, value at Mar. 31, 2019 | 306 | 366,838 | (394,424) | (27,280) | ||||||||
Issuance of common stock and warrants in private offerings, net of issuance costs and initial fair value of contingent payment rights | 6 | 54 | 60 | |||||||||
Issuance of common stock upon conversion | 5 | 43 | 48 | |||||||||
Share-based compensation, net of shares withheld for taxes | 48 | 48 | ||||||||||
Comprehensive loss for the period | (1,562) | (1,562) | ||||||||||
Balance, value at Jun. 30, 2019 | 317 | 366,983 | (395,986) | (28,686) | ||||||||
Issuance of common stock and warrants in private offerings, net of issuance costs and initial fair value of contingent payment rights | 180 | 180 | ||||||||||
Issuance of common stock upon exercise of warrants | 14 | 14 | ||||||||||
Issuance of convertible debt with beneficial conversion feature | 550 | 550 | ||||||||||
Issuance of common stock upon conversion | 4 | 51 | 55 | |||||||||
Share-based compensation, net of shares withheld for taxes | 286 | 286 | ||||||||||
Comprehensive loss for the period | (2,119) | (2,119) | ||||||||||
Balance, value at Sep. 30, 2019 | 335 | 368,050 | (398,105) | (29,720) | ||||||||
Balance, value at Dec. 31, 2019 | 341 | 368,345 | (401,783) | (33,097) | ||||||||
Issuance of common stock and warrants in private offerings, net of issuance costs and initial fair value of contingent payment rights | 39 | 2,811 | 2,850 | |||||||||
Issuance of common stock upon exercise of warrants | 14 | 487 | 501 | |||||||||
Issuance of common stock and warrants for services | 5 | 219 | 224 | |||||||||
Issuance of convertible debt with beneficial conversion feature | 173 | 173 | ||||||||||
Issuance of common stock upon conversion | 7 | $ 22 | 187 | $ 318 | 194 | $ 340 | ||||||
Share-based compensation, net of shares withheld for taxes | 3 | 458 | 461 | |||||||||
Comprehensive loss for the period | (7,921) | (7,921) | ||||||||||
Balance, value at Mar. 31, 2020 | 431 | 372,998 | (409,704) | (36,275) | ||||||||
Balance, value at Dec. 31, 2019 | 341 | 368,345 | (401,783) | (33,097) | ||||||||
Comprehensive loss for the period | (13,174) | |||||||||||
Balance, value at Sep. 30, 2020 | 520 | 375,370 | (414,957) | (39,067) | ||||||||
Balance, value at Mar. 31, 2020 | 431 | 372,998 | (409,704) | (36,275) | ||||||||
Issuance of common stock and warrants in private offerings, net of issuance costs and initial fair value of contingent payment rights | 43 | 725 | 768 | |||||||||
Issuance of common stock upon exercise of warrants | 11 | 363 | 374 | |||||||||
Issuance of common stock and warrants for services | 1 | 13 | 14 | |||||||||
Issuance of common stock upon conversion | 1 | 66 | 67 | |||||||||
Share-based compensation, net of shares withheld for taxes | 4 | 299 | 303 | |||||||||
Comprehensive loss for the period | (3,585) | (3,585) | ||||||||||
Balance, value at Jun. 30, 2020 | 491 | 374,464 | (413,289) | (38,334) | ||||||||
Issuance of common stock and warrants in private offerings, net of issuance costs and initial fair value of contingent payment rights | 15 | 215 | 230 | |||||||||
Issuance of common stock upon exercise of warrants | 10 | 340 | 350 | |||||||||
Issuance of common stock and warrants for services | 1 | 25 | 26 | |||||||||
Issuance of common stock upon conversion | $ 2 | $ 87 | $ 89 | |||||||||
Share-based compensation, net of shares withheld for taxes | 1 | 239 | 240 | |||||||||
Comprehensive loss for the period | (1,668) | (1,668) | ||||||||||
Balance, value at Sep. 30, 2020 | $ 520 | $ 375,370 | $ (414,957) | $ (39,067) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (13,174) | $ (5,775) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 497 | 604 |
Share-based compensation | 1,004 | 401 |
Noncash lease expense | 60 | 252 |
Loss (gain) on changes in fair value of contingent payment obligations | 3,487 | (755) |
Loss on disposal/impairment of equipment and other assets | 413 | 220 |
Noncash expense for amendment of equity-related agreements | 2,211 | |
Changes in operating assets and liabilities: | ||
Accounts receivable | 2 | |
Inventories | 77 | |
Prepaid expenses and other assets | 192 | 105 |
Accounts payable and accrued expenses | 1,302 | 1,759 |
Operating lease liabilities | (174) | (184) |
Total adjustments | 8,992 | 2,481 |
Net cash used in operating activities | (4,182) | (3,294) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Proceeds from sale of property and equipment | 27 | |
Purchases of property and equipment | (3) | (5) |
Payments for patent costs and other intangible assets | (18) | |
Net cash (used in) provided by investing activities | (3) | 4 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Net proceeds from issuance of common stock, including contingent payment rights, in private offerings | 3,057 | |
Net proceeds from exercise of options and warrants | 1,225 | 29 |
Net proceeds from debt financings | 1,244 | 2,665 |
Principal payments on long-term debt | (1,251) | (800) |
Principal payments on capital lease obligation | (1) | |
Net cash provided by financing activities | 4,275 | 1,893 |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 90 | (1,397) |
CASH AND CASH EQUIVALENTS, beginning of period | 57 | 1,527 |
CASH AND CASH EQUIVALENTS, end of period | $ 147 | $ 130 |
Description Of Business
Description Of Business | 9 Months Ended |
Sep. 30, 2020 | |
Description Of Business [Abstract] | |
Description Of Business | 1. Description of Business ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”) is in the business of innovating fundamental wireless technologies and products. We have designed and developed proprietary radio frequency (“ RF ”) technologies and integrated circuits for use in wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States of America (“U.S.”) and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others and therefore the primary focus of our business plan is the enforcement of our intellectual property rights through patent infringement litigation and licensing efforts. We currently have patent enforcement actions ongoing in various U.S. district courts against providers of mobile handset s and providers of smart televisions and other WiFi products and , in certain cases, their chip suppliers for the infringement of several of our RF patents. We have made significant investments in developing and protecting our technologies, the returns on which are dependent upon the generation of future revenues for realization. We also designed, developed and marketed a distributed WiFi product line under the brand name Milo®. We restructured our operations in 2018 to reduce operating expenses in light of our limited capital resources. Accordingly, we significantly reduced our ongoing investment in the Milo product s . In early 2019, we ceased substantially all ongoing research and development efforts and, where applicable, repurposed resources to support our patent enforcement and product sales and support efforts. We ceased sales of our Milo products in the fourth quarter of 2019 and are currently focused exclusively on our patent enforcement litigation and licensing efforts . |
Liquidity And Going Concern
Liquidity And Going Concern | 9 Months Ended |
Sep. 30, 2020 | |
Liquidity And Going Concern [Abstract] | |
Liquidity And Going Concern | 2. Liquidity and Going Concern Our accompanying condensed consolidated financial statements were prepared assuming we would continue as a going concern, which contemplates that we will continue in operation for the foreseeable future and will be able to realize assets and settle liabilities and commitments in the normal course of business for a period of at least one year from the issuance date of these condensed consolidated financial statements. These condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that could result should we be unable to continue as a going concern. We have incurred significant losses from operations and negative cash flows from operations in every year since inception and have utilized the proceeds from the sales of debt and equity securities and contingent funding arrangements with third parties to fund our operations, including the cost of litigation. For the nine months ended September 30, 2020, we incurred a net loss of approximately $13.2 million and negative cash flows from operations of approximately $4.2 million. At September 30 , 2020, we had cash and cash equivalents of approximately $0.1 million, a working capital deficit of approximately $4.8 million and an accumulated deficit of approximately $415.0 million. Additionally, a significant amount of future proceeds that we may receive from our patent enforcement and licensing programs will first be utilized to repay borrowings and legal fees and expenses under our contingent funding arrangements. These circumstanc es raise substantial doubt about our ability to continue to operate as a going concern for a period of one year following the issue date of these condensed consolidated financial statements. For the nine months ended September 30, 2020, we received aggregate net proceeds from debt and equity financings of approximately $4.3 million and proceeds from the exercise of outstanding warrants of approximately $1.2 million . In addition, we repaid approximately $0.7 million in short-term debt and other accrued expenses through the use of shares of our common stock. Despite these funding efforts, our resources are not sufficient to meet our short-term liquidity needs and we will be required to seek additional capital. Our ability to meet our liquidity needs for the next twelve months is dependent upon (i) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations and (ii) our ability to obtain additional debt or equity financing. We expect that proceeds received by us from patent enforcement actions and technology licenses over the next twelve months may not be sufficient to cover our working capital requirements. In the event we do not generate revenues, or other patent-related proceeds, sufficient to cover our operational costs and contingent repayment obligations, we will be required to raise additional working capital through the sale of equity securities or other financing arrangements. We are exploring additional financing opportunities for both our short and long-term capital needs. These financing opportunities may include debt, convertible debt, contingent payment rights, common or preferred equity offerings, or a combination thereof. There can be no assurance that we will be able to consummate a financing transaction or that the terms of such financing will be on terms and conditions that are acceptable. We expect to continue to invest in the support of our patent enforcement and licensing programs. The long-term continuation of our business plan is dependent upon the generation of sufficient revenues from our technologies and/or products to offset expenses and contingent payment obligations. In the event that we do not generate sufficient revenues, we will be required to obtain additional funding through public or private debt or equity financing or contingent fee arrangements and/or reduce operating costs. Failure to generate sufficient revenues, raise additional capital through debt or equity financings or contingent fee arrangements, and/or reduce operating costs will have a material adverse effect on our ability to meet our long-term liquidity needs and achieve our intended long-term business objectives. |
Basis Of Presentation
Basis Of Presentation | 9 Months Ended |
Sep. 30, 2020 | |
Basis Of Presentation [Abstract] | |
Basis Of Presentation | 3. Basis of Presentation The accompanying unaudited condensed consolidated financial statements for the period ended September 30, 2020 were prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or future years. All normal and recurring adjustments which, in the opinion of management, are necessary for a fair statement of the consolidated financial condition and results of operations have been included. The year-end condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2019, but does not include all disclosures required by GAAP. These interim condensed consolidated financial statements should be read in conjunction with our latest Annual Report on Form 10-K for the year ended December 31, 2019 (“2019 Annual Report”). The condensed consolidated financial statements include the accounts of ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts. |
Accounting Policies
Accounting Policies | 9 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
Accounting Policies | 4. Accounting Policies There have been no changes in accounting policies from those stated in our 2019 Annual Report. We do not expect any newly effective accounting standards to have a material impact on our financial position, results of operations or cash flows when they become effective , other than as described below. In August 2020, the FASB issued ASU 2020-06 "Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity . " This ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument and more convertible preferred stock as a single equity instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. The ASU also simplifies the diluted earnings per share (EPS) calculation in certain areas. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020 . We are evaluating the impact of ASU 2020-06 on our consolidated financial statements. |
Loss Per Common Share
Loss Per Common Share | 9 Months Ended |
Sep. 30, 2020 | |
Loss Per Common Share [Abstract] | |
Loss Per Common Share | 5. Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each period. Diluted loss per common share is the same as basic loss per common share as all common share equivalents are excluded from the calculation, as their effect is anti-dilutive. We have shares underlying outstanding options, warrants, unvested RSUs and convertible notes that were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive. These common share equivalents at September 30, 2020 and 2019 were as follows (in thousands): September 30, 2020 2019 Options outstanding 12,248 11,349 Warrants outstanding 13,850 12,150 Unvested RSUs 291 - Shares underlying convertible notes 23,807 20,846 50,196 44,345 |
Prepaid Expenses
Prepaid Expenses | 9 Months Ended |
Sep. 30, 2020 | |
Prepaid Expenses [Abstract] | |
Prepaid Expenses | 6. Prepaid Expenses Prepaid expenses consist of the following (in thousands): September 30, December 31, 2020 2019 Prepaid services $ 453 $ 221 Prepaid bonds for German statutory costs 136 188 Prepaid insurance 44 62 Prepaid licenses, software tools and support 11 17 Other prepaid expenses 16 17 $ 660 $ 505 Prepaid services include approximately $0.2 million and $0.1 million of consulting services paid in shares of stock or warrants to purchase shares of stock in the future at September 30, 2020, and December 31, 2019, respectively. |
Intangible Assets
Intangible Assets | 9 Months Ended |
Sep. 30, 2020 | |
Intangible Assets [Abstract] | |
Intangible Assets | 7. Intangible Assets Intangible assets consist of the following (in thousands): September 30, December 31, 2020 2019 Patents and copyrights $ 15,184 $ 16,612 Accumulated amortization (12,858) (13,734) $ 2,326 $ 2,878 |
Operating Lease Right-of-Use As
Operating Lease Right-of-Use Assets | 9 Months Ended |
Sep. 30, 2020 | |
Operating Lease Right-of-Use Assets [Abstract] | |
Operating Lease Right-of-Use Assets | 8. Operating Lease Right-of-Use Assets For the nine months ended September 30, 2020, we recognized an impairment loss of approximately $0.2 million on the right-of-use asset related to our Lake Mary office lease. We ceased use of this facility in 2018 as part of our restructuring of operation. The value of our right-of-use asset included estimated future sublease income. Due to a number of factors, including the high vacancy rate of the building in which the space is located and the current COVID-19 environment, we determined securing a sublease for the space would be unlikely. Accordingly, in 2020, we recognized an impairment loss, which represented the remaining carrying value of the asset. The impairment is included in selling, general, and administrative expenses in our condensed consolidated statements of comprehensive loss. |
Debt
Debt | 9 Months Ended |
Sep. 30, 2020 | |
Debt [Abstract] | |
Debt | 9. Debt Notes Payable Related Party Note Payable We have an unsecured promissory note of approximately $0.8 million payable to Sterne, Kessler, Goldstein, & Fox, PLLC (“SKGF”), a related party, for outstanding unpaid fees for legal services. The SKGF note, as amended, accrues interest at a rate of 4% per annum , requires repayments of principal and interest at a rate of $10,000 per month with a final balloon payment due in April 2022 . We are currently in compliance with all the terms of the note, as amended. Secured Note Payable We have a note payable to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“Mintz”) for outstanding, unpaid attorney’s fees and costs associated with our patent enforcement program. The Mintz note is non-interest bearing, except in the event of a default, and is secured by certain of our U.S. and foreign patents. The note, at Mintz’s option, accelerates and becomes immediately due and payable in the case of standard events of default and/or in the event of a sale or other transfer of substantially all of our assets or a transfer of more than 50% of our capital stock in one or a series of transactions or through a merger or other similar transaction. We have been in default on the payment terms of the note since November 17, 2019, and accordingly, have accrued interest at the default rate of 12% per annum. Currently, Mintz has not requested acceleration of unpaid principal and interest on the note, nor have they waived the outstanding default . During the nine months ended September 30 , 2020, we made payments to Mintz of $1.2 million , which we applied to outstanding principal and interest on the Mintz note, leaving an outstanding balance , including accrued default interest, at September 30 , 2020 of approximately $0.02 million. Mintz disputes our application of payments against principal and interest on the note rather than against the $3.1 million in billed and unpaid fees and expenses payable to Mintz included in accounts payable at September 30 , 2020. The unpaid fees and expenses payable to Mintz at September 30 , 2020 exclude approximately $3.6 million in fees billed by Mintz that are in excess of agreed-upon fee caps. We consider the excess fees to be a loss contingency that is not probable as of the issuance date of these condensed consolidated financial statements and, accordingly, we have not recognized these excess fees in expense for the period ended September 30, 2020. We are in discussions with Mintz to resolve our outstanding fee dispute with regard to amounts billed and payable as well as any success fees payable on potential future proceeds. Unsecured Notes Payable Unsecured notes payable at September 30, 2020 represents the current portion of our Paycheck Protection Program loan, as described more fully below. Unsecured notes payable at December 31, 2019 represents the outstanding principal balance of unsecured short-term promissory notes with accredited investors for aggregate proceeds of approximately $0.23 million. The short-term promissory notes , as amended, accrued interest at a rate of 20% per annum . During the nine months ended September 30, 2020, we issued an aggregate of 1,740,426 shares of our common stock as an in-kind repayment of all outstanding principal and accrued interest on these short-term notes . Paycheck Protection Program Loan In May 2020, we received approximately $0.2 million in proceeds from an approved loan under the Paycheck Protection Program. Interest will accrue on outstanding principal balance at a rate of 1% , computed on a simple interest basis. The loan principal and accrued interest will be eligible for forgiveness provided that (i) we used the loan proceeds exclusively for allowed costs including payroll, employee group health benefits, rent and utilities and (ii) employee and compensation levels were maintained during the coverage period. If the loan is not forgiven, we will be required to make monthly repayments of approximately $8,000 per month commencing May 1, 2021 and the loan will mature on May 3, 2022, at which time any unpaid principal and accrued interest will be due and payable. The current and noncurrent portions of this loan are included in the captions “Unsecured notes payable” and “Other long-term liabilities” in the condensed consolidated balance sheet as of September 30, 2020. Convertible Notes Our convertible notes represent five -year promissory notes that are convertible, at the holders’ option, into shares of our common stock at fixed conversion prices. The notes bear interest at a stated rate of 8% per annum , except for the July 18, 2019 notes which bear interest at a stated rate of 7.5% per annum. Interest is payable quarterly, and we may elect to pay interest in either cash, shares of our common stock, or a combination thereof, subject to certain equity conditions. To date, all interest payments on the convertible notes have been made in shares of our common stock , including payments of $0.22 million during the nine months ended September 30, 2020. We have the option to prepay the majority of the notes any time following the one-year anniversary of the issuance of the notes, subject to a premium on the outstanding principal prepayment amount of 25% prior to the two-year anniversary of the note issuance date, 20% prior to the three-year anniversary of the note issuance date, 15% prior to the four-year anniversary of the note issuance date, or 10% thereafter. We do not have a prepayment option with regard to the July 18, 2019 notes or the January 8, 2020 notes. Notes with a principal balance of $0.13 million were converted, at the option of the holder, into shares of our common stock during the nine-month period ended September 30, 2020. Convertible notes payable at September 30, 2020 and December 31, 2019 consist of the following (in thousands): Fixed Effective Principal Outstanding as of Conversion Interest September 30, December 31, Description Rate Rate 1 Maturity Date 2020 2019 Convertible notes dated September 10, 2018 $0.40 23.4% September 7, 2023 $ 600 $ 700 Convertible note dated September 19, 2018 $0.57 10.2% September 19, 2023 425 425 Convertible notes dated February/March 2019 $0.25 8.0% February 28, 2024 to March 13, 2024 1,300 1,300 Convertible notes dated June/July 2019 $0.10 8.0% June 7, 2024 to July 15, 2024 365 390 Convertible notes dated July 18, 2019 $0.08 46.1% July 18, 2024 700 700 Convertible notes dated September 13, 2019 $0.10 25.9% September 13, 2024 50 50 Convertible notes dated January 8, 2020 $0.13 20.3% January 8, 2025 450 - Total principal balance 3,890 3,565 Less Unamortized discount 880 832 $ 3,010 $ 2,733 1 Notes with an effective interest rate in excess of 8% represent notes that were issued with a beneficial conversion feature meaning that the conversion price of the note was below the market price of our common stock at closing. The value of the beneficial conversion feature is recognized as a discount on the note with a corresponding credit to additional paid in capital at inception. The note discount is amortized over the five -year term of the note. Secured Contingent Payment Obligation The following table provides a reconciliation of our secured contingent payment obligation, measured at estimated fair market value, for the nine months ended September 30, 2020 and the year ended December 31, 2019 (in thousands) : Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Secured contingent payment obligation, beginning of period $ 26,651 $ 25,557 Change in fair value 2,137 1,094 Secured contingent payment obligation, end of period $ 28,788 $ 26,651 Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell Key Investments, LP (“Brickell”) under a February 2016 funding agreement, as amended. Brickell is entitled to priority payment of 55% to 100% of proceeds received from all patent-related actions until such time that Brickell has been repaid in full. After repayment of the funded amount, which is $14.7 million as of September 30, 2020, Brickell is entitled to a portion of remaining proceeds up to a specified minimum return which is determined as a percentage of the funded amount and varies based on the timing of repayment and the origin of the proceeds. In addition, Brickell is entitled to a pro rata portion of proceeds from specified legal actions to the extent aggregate proceeds from those actions exceed the specified minimum return. The range of potential proceeds payable to Brickell is discussed more fully in Note 10. As of September 30, 2020, we are in compliance with our obligations under this agreement. We have elected to measure our secured contingent payment obligation at fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods. The secured contingent payment obligation is remeasured to fair value at each reporting period with changes recorded in the condensed consolidated statements of comprehensive loss until the contingency is resolved (see Note 10). Unsecured Contingent Payment Obligations The following table provides a reconciliation of our unsecured contingent payment obligations, measured at estimated fair market value, for the nine months ended September 30, 2020 and the year ended December 31, 2019 (in thousands) : Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Unsecured contingent payment obligations, beginning of period $ - $ - Reclassification of other liabilities 1,003 - Proceeds from sale of contingent payment rights 984 - Initial fair market value of modification 436 - Change in fair value 1,350 - Unsecured contingent payment obligations, end of period $ 3,773 $ - Our unsecured contingent payment obligations represent amounts payable to others from future patent-related proceeds including (i) a termination fee due to a litigation funder (“Termination Fee”) and (ii) contingent payment rights issued to accredited investors in connection with equity financings (“CPRs”). We have elected to measure these unsecured contingent payment obligations at their estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods. The unsecured contingent payment obligations will be remeasured to fair value at each reporting period with changes recorded in the condensed consolidated statements of comprehensive loss until the contingency is resolved (see Note 10). The Termination Fee is a result of $1.0 million received as advances under a letter agreement with a third-party funder. Based on the terms of the letter agreement, if a final funding arrangement was not executed by March 31, 2020, we would be obligated to pay, from future patent-related proceeds, an aggregate termination payment equal to five times the upfront payment received, or $5.0 million. We did not reach an agreement as of March 31, 2020 and formally terminated negotiations in April 2020. Advances under the letter agreement included $0.4 million as of December 31, 2019, and $0.6 million advanced in January 2020. The advances, which were initially recorded in other long-term liabilities, were reclassified to unsecured contingent payment obligations at March 31, 2020 when the Termination Fee obligation was incurred. As of September 30, 2020, the estimated fair value of unsecured contingent payment obligations related to the Termination Fee is $2.4 million. The CPRs represent the estimated fair value of rights provided to accredited investors who purchased shares of our common stock between March and August 2020 (see Note 12). During the nine months ended September 30, 2020, we received proceeds of $2.1 million from the sale of common stock with contingent payment rights, of which approximately $1.0 million was allocated to the CPRs. In addition, on May 1, 2020, we granted CPRs to investors who purchased $0.9 million of our common stock in March 2020, resulting in a charge to expense of $0.4 million for the initial estimated fair value of the CPRs. The terms of the CPRs provide that we will pay each investor an allocated portion of our net proceeds from patent-related actions, after taking into account fees and expenses payable to law firms representing us and amounts payable to Brickell. The investors’ allocated portion of net proceeds will be determined by multiplying the net proceeds recovered by us (up to $10 million) by the quotient of such investors’ subscription amount divided by $10 million, up to an amount equal to each investor’s subscription amount, or an aggregate of $3.0 million. As of September 30, 2020, the estimated fair value of our unsecured contingent payment obligations related to the CPRs is $1.4 million. |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2020 | |
Fair Value Measurements [Abstract] | |
Fair Value Measurements | 10. Fa ir Value Measurements The following tables summarize the fair value of our assets and liabilities measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 (in thousands): Fair Value Measurements Total Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2020: Liabilities: Secured contingent payment obligation $ 28,788 $ - $ - $ 28,788 Unsecured contingent payment obligations 3,773 - - 3,773 Fair Value Measurements Total Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2019: Liabilities: Secured contingent payment obligation $ 26,651 $ - $ - $ 26,651 The fair values of our secured and unsecured contingent payment obligations were estimated using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate. We used a risk-adjusted discount rate of 14.15% at September 30, 2020, based on a risk-free rate of 0.15% as adjusted by 8% for credit risk and 6% for litigation inherent risk. The following table provides quantitative information about the significant unobservable inputs used in the measurement of fair value for both the secured and unsecured contingent payment obligations at September 30, 2020, including the lowest and highest undiscounted payout scenarios as well as a weighted average payout scenario based on relative undiscounted fair value of each cash flow scenario. Secured Contingent Payment Obligation Unsecured Contingent Payment Obligations Unobservable Inputs Low Weighted Average High Low Weighted Average High Estimated undiscounted cash outflows (in millions) $0.0 $39.3 $58.5 $0.0 $5.1 $8.0 Duration (in years) 1.0 2.4 3.0 1.0 2.4 3.0 Estimated probabilities 0% 13% 30% 2% 22% 38% We evaluate the estimates and assumptions used in determining the fair value of our contingent payment obligations each reporting period and make any adjustments prospectively based on those evaluations. Changes in any of these Level 3 inputs could result in a significantly higher or lower fair value measurement. |
Legal Proceedings
Legal Proceedings | 9 Months Ended |
Sep. 30, 2020 | |
Legal Proceedings [Abstract] | |
Legal Proceedings | 11. Legal Proceedings From time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business. These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”) and in the Federal Patent Court in Germany in an attempt to invalidate certain of our patent claims. We had several patent enforcement actions in Germany, which has a “loser pay” system whereby the non-prevailing party is responsible for statutory attorney fees and costs. To the extent a loss is probable and reasonably estimable as of the balance sheet date, the estimated loss is recorded in the accompanying condensed consolidated statements of comprehensive loss and included in current liabilities under the heading “statutory court costs” in the condensed consolidated balance sheets. As of September 30, 2020, and December 31, 2019, we have accrued an aggregate of $0.24 million and $0.37 million, respectively , in estimated statutory court costs for our cases in Germany. United States Proceedings ParkerVision v. Qualcomm (Middle District of Florida) We have a patent infringement complaint pending in the Middle District of Florida against Qualcomm and Qualcomm Atheros, Inc. (collectively “Qualcomm”) seeking approximately $1.3 billion in damages for infringement of four of our patents (the “Qualcomm Action”) . HTC (HTC Corporation and HTC America, Inc.) was also a defendant in this case but we voluntarily dismissed our claims against HTC and HTC dismissed their related counter-claims against us in October 2020. Qualcomm has pending counterclaims against us for non-infringement and invalidity for all patents in the case. The case was filed in May 2014 and stayed in February 2016 pending decisions in other cases, including the appeal of a PTAB proceeding with regard to U.S. patent 6,091,940 (“the ‘940 Patent”) asserted in this case. In March 2017, the PTAB ruled in our favor on three of the six petitions (the method claims), ruled in Qualcomm’s favor on two of the six petitions (the apparatus claims) and issued a split decision on the claims covered in the sixth petition. In September 2018, the Federal Circuit upheld the PTAB’s decision with regard to the ‘940 Patent and, in January 2019, the court lifted the stay in this case. In July 2019, the court issued an order that granted our proposed selection of patent claims from four asserted patents, including the ‘940 Patent, and denied Qualcomm’s request to limit the claims and patents. The court also agreed that we may elect to pursue accused products that were at issue at the time the case was stayed, as well as new products that were released by Qualcomm during the pendency of the stay. In September 2019, Qualcomm filed a motion for partial summary judgement in an attempt to exclude certain patents from the case, including the ‘940 Patent. The court denied this motion in January 2020. In April 2020, the c ourt issued its claim construction order in which the court adopted our proposed construction for seven of the ten disputed terms and adopted slightly modified versions of our proposed construction for the remaining terms . In October 2020, our damages expert submitted a report concluding that $1.3 billion is the reasonable royalty owed by Qualcomm for its unauthorized use of our technology, excluding additional amounts requested by us for interest and enhanced damages for willful infringement. Ultimately, these amounts will be determined by the court. Discovery is expected to close in December 2020 and a trial is scheduled to commence on May 3, 2021. The law firm of McKool Smith is representing us in this case on a contingency fee basis. ParkerVision v. Apple and Qualcomm (Middle District of Florida) In December 2015, we filed a patent infringement complaint in the Middle District of Florida against Apple, LG, Samsung and Qualcomm alleging infringement of four of our patents. In February 2016, the district court proceedings were stayed pending resolution of a corresponding case filed at the International Trade Commission (“ITC”). In July 2016, we entered into a patent license and settlement agreement with Samsung and, as a result, Samsung was dismissed from the district court action. In March 2017, we filed a motion to terminate the ITC proceedings and a corresponding motion to lift the stay in the district court case. This motion was granted in May 2017. In July 2017, we filed a motion to dismiss LG from the district court case (see ParkerVision v. LG below). Also in July 2017, Qualcomm filed a motion to change venue to the southern district of California , and Apple filed a motion to dismiss for improper venue. In March 2018, the district court ruled against the Qualcomm and Apple motions. The parties also filed a joint motion in March 2018 to eliminate three of the four patents in the case in order to expedite proceedings leaving our U.S. patent 9,118,528 as the only remaining patent in this case. A claim construction hearing was held on August 31, 2018. In July 2019, the court issued its claim construction order in which the court adopted our proposed claim construction for two of the six terms and the “plain and ordinary meaning” on the remaining terms. In addition, the court denied a motion filed by Apple for summary judgment. Fact discovery has closed in this case and a jury trial wa s scheduled to begin in August 2020. In March 2020, as a result of the impact of COVID-19, the parties filed a motion requesting an extension of certain deadlines in the case. In April 2020, the court stayed this proceeding pending the outcome of the Qualcomm Action. The law firm of Mintz Levin is representing us in this case on a partial contingency fee basis. ParkerVision v. LG (District of New Jersey) In July 2017, we filed a patent infringement complaint in the District of New Jersey against LG for the alleged infringement of the same patents previously asserted against LG in Florida (see ParkerVision v. Apple and Qualcomm above). We elected to dismiss the case in Florida and re-file in New Jersey as a result of a Supreme Court ruling regarding proper venue. In March 2018, the court stayed this case pending a final decision in ParkerVision v. Apple and Qualcomm in the Middle District of Florida. As part of this stay, LG has agreed to be bound by the final claim construction decision in that case. ParkerVision v. Intel (Western District of Texas) In February 2020, we filed a patent infringement complaint in the Western District of Texas against Intel alleging infringement of eight of our patents. The complaint was amended in May 2020 to add two additional patents. In June 2020, we requested that one of the patents be dropped from this case and filed a second case in the Western District of Texas that included this dismissed patent (see ParkerVision v. Intel II below). Intel’s response to our complaint was filed in June 2020 denying infringement and claiming invalidity of the patents. Intel has also filed a motion to transfer venue which has not yet been ruled on by the court. The claim construction hearing is currently scheduled for January 22, 2021 and the case is scheduled for trial beginning February 7, 2022. The law firm of Goldberg Segalla is representing us in this case on a contingency fee basis. Intel v. ParkerVision (PTAB) Intel filed petitions for Inter Partes Review (IPR) against U.S. patent 7,539,474 (“the ‘474 Patent”) and U.S. patent 7,110,444 (“the ‘444 Patent”), both of which are patents asserted in ParkerVision v. Intel . Our preliminary responses to the petitions are due late in the fourth quarter of 2020 following which the PTAB will make its decision as to whether to institute or dismiss the review proceedings. ParkerVision v. Intel II (Western District of Texas) In June 2020, to reduce the number of claims in ParkerVision v. Intel , we filed a second patent infringement complaint in the Western District of Texas against Intel that included a single patent that we voluntarily dismissed from the original case. In July 2020, we amended our complaint adding two more patents to the case. The claim construction hearing is currently scheduled for February 25, 2021 and the case is scheduled for trial beginning March 17, 2022. The law firm of Goldberg Segalla is representing us in this case on a contingency fee basis. ParkerVision v. TCL (Central District of California) In May 2020, we filed a patent infringement complaint against TCL Technology Group Corp, a Chinese company, and its U.S. subsidiary, TTE Technology, Inc. in the Central District of California alleging infringement of ten of our patents. In October 2020, we voluntarily dismissed this case without prejudice and filed a corresponding complaint in the Western District of Texas (see below). ParkerVision v. TCL (Western District of Texas) In October 2020, we filed a patent infringement complaint against TCL Industries Holdings Co., Ltd, a Chinese company, TCL Electronics Holdings Ltd., Shenzhen TCL New Technology Co., Ltd, TCL King Electrical Appliances (Huizhou) Co., Ltd., TCL Moka Int’l Ltd. and TCL Moka Manufacturing S.A. DE C.V. (collectively “TCL”) in the Western District of Texas alleging infringement of ten of our patents. TCL products included in the action incorporate modules that contain certain Wi-Fi chips manufactured by Realtek. The law firm of Goldberg Segalla is representing us in this case on a contingency fee basis. ParkerVision v. Hisense (Western District of Texas) In September 2020, we filed a patent infringement complaint against Hisense Co., Ltd. and Hisense Visual Technology Co., Ltd (collectively “Hisense”), a Chinese company, in the Western District of Texas alleging infringement of ten of our patents. Hisense products included in the action incorporate modules that contain certain Wi-Fi chips manufactured by Realtek and MediaTek. The law firm of Goldberg Segalla is representing us in this case on a contingency fee basis. ParkerVision v. Buffalo (Western District of Texas) In October 2020, we filed a patent infringement complaint against Buffalo Inc., a Japanese company, (“Buffalo”), in the Western District of Texas alleging infringement of ten of our patents. Buffalo products included in the action incorporate modules that contain certain Wi-Fi chips manufactured by Realtek and MediaTek. The law firm of Goldberg Segalla is representing us in this case on a contingency fee basis. ParkerVision v .Zyxel (Western District of Texas) In October 2020, we filed a patent infringement complaint against Zyxel Communications Corporation, a Chinese multinational electronics company headquartered in Taiwan, (“Zyxel”), in the Western District of Texas alleging infringement of ten of our patents. Zyxel products included in the action incorporate modules that contain certain Wi-Fi chips manufactured by Realtek and MediaTek. The law firm of Goldberg Segalla is representing us in this case on a contingency fee basis. The cases filed against Zyxel, Buffalo, Hisense, and TCL in the Western District of Texas all assert the same ten patents. German Proceedings ParkerVision v. LG Electronics (Munich, Germany) In June 2016, we filed a complaint in Munich District Court against LG Electronics Deutschland GmbH, a German subsidiary of LG Electronics, Inc. (“LGE”) seeking damages and injunctive relief for the alleged infringement of the German part of our European patent 1 206 831 (“the ‘831 Patent”). In November 2016, the court concluded that certain LGE products using Qualcomm RF circuitry infringe our patent. However, t he final decision in this case was stayed pending resolution of the corresponding nullity, or validity, action filed by Qualcomm in the German Federal Patent Court in Munich (see Qualcomm v. ParkerVision below). In October 2018, we received an unfavorable decision in the nullity case . As a result, our infringement complaint in this case was dismissed . As the non-prevailing party , we were subject to claim s for reimbursement of statutory attorney’s fees and costs in this case which were covered in full by a bond we posted in this case. Qualcomm v. ParkerVision – Federal Patent Court in Germany (as appealed to the German Supreme Court) In August 2016, Qualcomm filed a validity action in Federal Patent Court in Germany against the ’831 Patent. The outcome of this validity action impacts our German patent infringement cases against LGE and Apple as discussed above. On October 17, 2018, following an oral hearing, the court ruled that the ‘831 Patent was invalid. In January 2019, we appealed this decision to the German Supreme Court, but withdrew our appeal in July 2019. As the non-prevailing party, we are subject to claims for reimbursement of statutory fees and costs in this case, which are accrued in the accompanying condensed consolidated financial statements as of September 30, 2020 and December 31, 2019 . ParkerVision v. Apple (Munich, Germany) – the Apple II case The Apple II case sought damages and injunctive relief for the alleged infringement of the German part of our European patent 1 135 853 (“the ‘853 Patent”). The court ruled in April 2019 that Apple does not infringe our ‘853 Patent. We did not appeal this decision. As the non-prevailing party , we are subject to claim s for reimbursement of statutory attorney’s fees and costs in this case which we have accrued in the accompanying condensed consolidated financial statements as of September 30, 2020 and December 31, 2019 . We have posted a bond to cover this cost which is included in “Prepaid expenses” in the accompanying condensed consolidated balance sheets. We have requested a release of the bond which is expected to fully cover the costs in this case. Intel v. ParkerVision (Federal Patent Court in Germany) In August 2017, Intel filed a nullity action in German Federal Patent Court claiming invalidity of the ‘853 Patent that is the subject of the Apple II case. In December 2019, following the adverse decision in the Apple II case, we elected not to proceed with a defense in this case. As the non-prevailing party, we were subject to claims for reimbursement of statutory attorney fees and costs in this case which were accrued in the accompanying condensed consolidated financial statements as of December 31, 2019 and which were fully paid in September 2020 . |
Stock Issuance
Stock Issuance | 9 Months Ended |
Sep. 30, 2020 | |
Stock Issuance [Abstract] | |
Stock Issuance | 12 . Sto c k Issuance Stock and Warrant Issuances – Equity Based Financings Private Placements with Accredited Investors I n January 2020, we entered into securities purchase agreements with accredited investors for an aggregate of 1,169,232 shares of our common stock at a price of $0.13 per share and 166,667 shares of our common stock at $0.15 per share for aggregate proceeds of approximately $0.2 million. In March 2020, we entered into securities purchase agreements with accredited investors for an aggregate of 2,571,432 shares of our common stock at a price of $0.35 per share for aggregate proceeds of $0.9 million. The shares were registered for resale on a registration statement that was declared effective on April 28, 2020 (File No. 333-237762). The securities purchase agreements for the March 2020 transaction were amended on May 1, 2020 , in order to add a contingent p ayment right whereby we will pay each i nvestor an allocated portion of our share of proceeds from patent-related actions, after taking into account fees and expenses payable to law firms representing the Company and amounts payable to Brickell, up to an amount equal to the investors’ aggregate subscription amount, or $0.9 million . This amendment resulted in the recognition of $0.4 million in expense to recognize the initial fair value of the contingent payment right (see “unsecured contingent payment obligations” in Note 9). During the nine months ended September 30, 2020, we entered into securities purchase agreements with accredited investors for an aggregate of 5,871,584 shares of our common stock at a price of $0.35 per share for aggregate proceeds of $2.1 million. The securities purchase agreements include contingent payment rights. Approximately $1.0 million of the proceeds were allocated to unsecured contingent payment obligations based on the initial fair value estimate of the CPRs (see Note 9). The shares were registered for resale on a registration statement that was declared effective on September 2, 2020 (File No. 333-248242). Warrant Amendment with Aspire Capital On February 28, 2020, we entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with Aspire Capital Fund, LLC (“Aspire”), with respect to warrants issued in July and September 2018 (the “2018 Warrants”) that are exercisable, collectively, into 5,000,000 shares of our common stock . The Warrant Amendment Agreement provided for a reduction in the exercise price for the 2018 Warrants from $0.74 to $0.35 per share and the issuance of a new warrant for the purc hase of 5,000,000 shares of our common stock at an exercise price of $0.74 per share (“New Aspire Warrant”). The New Aspire Warrant expires February 28, 2025 and is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets to our stockholders. The New Aspire Warrant contains provisions that prohibit exercise if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. The holder of the New Aspire Warrant may increase (up to 19.99% ) or decrease this percentage by providing at least 61 days’ prior notice to the Company. In the event of certain corporate transactions, the holder of the New Aspire Warrant will be entitled to receive, upon exercise of such New Aspire Warrant, the kind and amount of securities, cash or other property that the holder would have received had they exercised the New Aspire Warrant immediately prior to such transaction. The New Aspire Warrant does not contain voting rights or any of the other rights or privileges as a holder of our common stock . The Warrant Amendment Agreement added a call provision to the 2018 Warrants whereby we may, after December 31, 2020, call for cancellation of all or any portion of the 2018 Warrants for which an exercise notice has not yet been received, in exchange for consideration equal to $0.001 per warrant share and subject to certain conditions, including the continued existence of an effective registration statement for the underlying shares of common stock and the availability of sufficient authorized shares to allow for the exercise of the 2018 Warrants. All other terms of the 2018 Warrants remained unchanged, including the original expiration dates of July and September 2023. In connection with the Warrant Amendment Agreement, Aspire exercised 1,430,000 shares of the 2018 Warrants for aggregate proceeds to us of $0.5 million . An additional 1,070,000 shares of the 2018 Warrants were exercised during the nine months ended September 30, 2020 for aggregate proceeds to us of $0.38 million. We recognized $1.78 million of non-cash warrant expense in connection with the Warrant Amendment Agreement based on the difference between the Black-Scholes value of the warrants immediately before and after the amendment. T he shares underlying the New Aspire Warrant were registered for resale on a registration statement that was declared effective on April 28, 2020 (File No. 333-23 7762 ). The shares underlying the 2018 Warrants are currently registered for resale pursuant to a registration statement on Form S-1 (File No. 333-226738). Stock and Warrant Issuances – Payment for Services On February 10, 2020, we entered into a business consulting and retention agreement with Chelsea Investor Relations (“Chelsea”) to provide business advisory services to us. As consideration for services to be provided under the 24 -month term of the consulting agreement, we issued 500,000 shares of unregistered common stock in exchange for a nonrefundable retainer for services valued at approximately $0.15 million . The value of the stock issued is being recognized as consulting expense over the term of the agreement. The shares were registered for resale on a registration statement that was declared effective on April 28, 2020 (File No. 333-23 7762 ). On March 16, 2020, we entered into an agreement with Tailwinds Research Group LLC (“Tailwinds”) to provide digital marketing services to us. As consideration for services to be provided under the twelve -month term of the agreement, we issued warrants for the purchase up to 200,000 shares of our common stock with an exercise price of $1.00 per share in exchange for a nonrefundable retainer for services, valued using the Black-Scholes method, at approximately $0.06 million. The value of the warrants is being recognized as expense over the term of the agreement. The Tailwinds warrants are exercisable immediately after issuance, expire March 16, 2023, and are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock . T he shares underlying the warrant were registered for resale on a registration statement that was declared effective on April 28, 2020 (File No. 333-23 7762 ). On June 8, 2020, we entered into an agreement with a third party to provide media advisory services. As consideration for services to be provided under the term of the agreement, which extends through December 31, 2020, we issued 30,000 shares of unregistered common stock for a nonrefundable retainer for services valued at approximately $0.01 million. The value of the stock issued is being recognized as a consulting expense over the term of the agreement. We are not obligated to register the shares for resale. In July 2020, we issued 50,000 shares of our unregistered common stock, valued at approximately $0.03 million, as compensation for shareholder awareness services provided by a third party during the second quarter of 2020. The agreement provides for future issuances of 50,000 shares for up to three successive three-month periods over the term of the agreement, unless the services are terminated in accordance with the agreement. In October 2020, we issued an additional 50,000 shares of our unregistered common stock, valued at approximately $0.02 million, as compensation for services provided by this third party during the third quarter of 2020. Common Stock Warrants As of September 30, 2020 , we had outstanding warrants for the purchase of up to 13.9 million shares of our common stock. The estimated grant date fair value of these warrants of $2.0 million is included in Additional Paid-in Capital in our condensed consolidated balance sheets. As of September 30, 2020, our outstanding warrants have an average exercise price of $0.44 per share and a weighted average remaining life of approximately 3.3 years. |
Share-Based Compensation
Share-Based Compensation | 9 Months Ended |
Sep. 30, 2020 | |
Share-Based Compensation [Abstract] | |
Share-Based Compensation | 13. Share-Based Compensation There has been no material change in the assumptions used to compute the fair value of our equity awards, nor in the method used to account for share-based compensation from those stated in our 2019 Annual Report. The following table presents share-based compensation expense included in our condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2020 and 2019, respectively (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Research and development expenses $ - $ - $ - $ 5 Selling, general and administrative expenses 240 286 1,004 396 Total share-based compensation expense $ 240 $ 286 $ 1,004 $ 401 As of September 30, 2020, there was $0.6 million of total unrecognized compensation cost related to all non-vested share-based compensation awards. The cost is expected to be recognized over a weighted-average period of approximately 1 year. On January 14, 2020, the Board granted nonqualified stock options to purchase 218,000 shares at an exercise price of $0.21 and 171,000 restricted shares awards (“RSAs”) to former directors in settlement of approximately $0.3 million in past Board and committee compensation fees. The options and RSAs vest immediately upon grant and the options expire five years from the grant date. On February 9, 2020, the Board approved awards under the Company’s 2019 Long Term Incentive Plan (the “2019 Plan”) to executives and other key employees. The awards included 675,000 restricted share units (“RSUs”) and 150,000 nonqualified stock options at an exercise price of $0.33 per share. Fi fty percent ( 50% ) of the RSUs vest on May 9, 2020 and the remaining RSUs vest in four equal quarterly installments commencing August 9, 2020. The options vest 50% upon grant with the remainder vesting in four equal quarterly installments commencing May 10, 2020. In addition, on February 9, 2020, the Board approved equity awards to independent directors under the 2019 Plan for the directors’ continued waiver of all cash fees for board or committee service. The awards included 150,000 RSUs and 300,000 nonqualified stock options at an exercise price of $0.33 per share. The non-employee director awards vest 50% upon grant with the remaining portion vesting in four equal quarterly installments commencing May 9, 2020. The Board also awarded an immediately vested option to purchase 100,000 shares at an exercise price of $0.33 per share under the Company’s 2011 Long Term Incentive Equity Plan to Robert Sterne in exchange for Mr. Sterne’s waiver of approximately $0.1 million in accrued and unpaid fees for board and committee service from 2016 to 2018. Each of the options awarded expire on February 9, 2027. Non-Employee Compensation On June 7 , 2020, we extended our 2019 business consulting and retention agreement with Mark Fisher to provide business advisory services to us through 2020 . As consideration for services to be provided under the 12 -month term of the consulting agreement, we issued a restricted stock award (RSA) of 20,000 shares of common stock through the 2019 Long Term Incentive Plan in exchange for a nonrefundable retainer for services valued at approximately $0.01 million . The value of the shares issued was recognized as share-based compensation at the time of issuance. |
Loss Per Common Share (Tables)
Loss Per Common Share (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Loss Per Common Share [Abstract] | |
Summary Of Anti-Dilutive Shares | September 30, 2020 2019 Options outstanding 12,248 11,349 Warrants outstanding 13,850 12,150 Unvested RSUs 291 - Shares underlying convertible notes 23,807 20,846 50,196 44,345 |
Prepaid Expenses (Tables)
Prepaid Expenses (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Prepaid Expenses [Abstract] | |
Schedule Of Prepaid Expenses | September 30, December 31, 2020 2019 Prepaid services $ 453 $ 221 Prepaid bonds for German statutory costs 136 188 Prepaid insurance 44 62 Prepaid licenses, software tools and support 11 17 Other prepaid expenses 16 17 $ 660 $ 505 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Intangible Assets [Abstract] | |
Schedule Of Intangible Assets | Intangible assets consist of the following (in thousands): September 30, December 31, 2020 2019 Patents and copyrights $ 15,184 $ 16,612 Accumulated amortization (12,858) (13,734) $ 2,326 $ 2,878 |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Debt Instrument [Line Items] | |
Schedule Of Convertible Notes Payable | Fixed Effective Principal Outstanding as of Conversion Interest September 30, December 31, Description Rate Rate 1 Maturity Date 2020 2019 Convertible notes dated September 10, 2018 $0.40 23.4% September 7, 2023 $ 600 $ 700 Convertible note dated September 19, 2018 $0.57 10.2% September 19, 2023 425 425 Convertible notes dated February/March 2019 $0.25 8.0% February 28, 2024 to March 13, 2024 1,300 1,300 Convertible notes dated June/July 2019 $0.10 8.0% June 7, 2024 to July 15, 2024 365 390 Convertible notes dated July 18, 2019 $0.08 46.1% July 18, 2024 700 700 Convertible notes dated September 13, 2019 $0.10 25.9% September 13, 2024 50 50 Convertible notes dated January 8, 2020 $0.13 20.3% January 8, 2025 450 - Total principal balance 3,890 3,565 Less Unamortized discount 880 832 $ 3,010 $ 2,733 1 Notes with an effective interest rate in excess of 8% represent notes that were issued with a beneficial conversion feature meaning that the conversion price of the note was below the market price of our common stock at closing. The value of the beneficial conversion feature is recognized as a discount on the note with a corresponding credit to additional paid in capital at inception. The note discount is amortized over the five -year term of the note. |
Unsecured Debt [Member] | |
Debt Instrument [Line Items] | |
Reconciliation Of Secured Contingent Obligation At Fair Value | Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Unsecured contingent payment obligations, beginning of period $ - $ - Reclassification of other liabilities 1,003 - Proceeds from sale of contingent payment rights 984 - Initial fair market value of modification 436 - Change in fair value 1,350 - Unsecured contingent payment obligations, end of period $ 3,773 $ - |
Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Reconciliation Of Secured Contingent Obligation At Fair Value | Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Secured contingent payment obligation, beginning of period $ 26,651 $ 25,557 Change in fair value 2,137 1,094 Secured contingent payment obligation, end of period $ 28,788 $ 26,651 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Fair Value Measurements [Abstract] | |
Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis | Fair Value Measurements Total Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2020: Liabilities: Secured contingent payment obligation $ 28,788 $ - $ - $ 28,788 Unsecured contingent payment obligations 3,773 - - 3,773 Fair Value Measurements Total Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2019: Liabilities: Secured contingent payment obligation $ 26,651 $ - $ - $ 26,651 |
Quantitative Information | Secured Contingent Payment Obligation Unsecured Contingent Payment Obligations Unobservable Inputs Low Weighted Average High Low Weighted Average High Estimated undiscounted cash outflows (in millions) $0.0 $39.3 $58.5 $0.0 $5.1 $8.0 Duration (in years) 1.0 2.4 3.0 1.0 2.4 3.0 Estimated probabilities 0% 13% 30% 2% 22% 38% |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Share-Based Compensation [Abstract] | |
Schedule Of Share-Based Compensation Expense Included In Statements Of Operations | Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Research and development expenses $ - $ - $ - $ 5 Selling, general and administrative expenses 240 286 1,004 396 Total share-based compensation expense $ 240 $ 286 $ 1,004 $ 401 |
Liquidity And Going Concern (De
Liquidity And Going Concern (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | |
Liquidity And Going Concern [Abstract] | |||||
Net loss | $ (1,668) | $ (2,119) | $ (13,174) | $ (5,775) | |
Net cash used in operating activities | (4,182) | $ (3,294) | |||
Accumulated deficit | (414,957) | (414,957) | $ (401,783) | ||
Net working capital | (4,800) | (4,800) | |||
Cash, cash equivalents and available for sale securities | $ 100 | 100 | |||
Proceeds from sale of debt and equity securities | 4,300 | ||||
Proceeds from Warrant Exercises | 1,200 | ||||
Repayment of debt and accrued expenses | $ 700 |
Loss Per Common Share (Details)
Loss Per Common Share (Details) - shares shares in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Shares excluded from the computation of diluted loss per share | 50,196 | 44,345 |
Stock Options [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Shares excluded from the computation of diluted loss per share | 12,248 | 11,349 |
Warrants Outstanding [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Shares excluded from the computation of diluted loss per share | 13,850 | 12,150 |
Restricted Stock Units (RSUs) [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Shares excluded from the computation of diluted loss per share | 291 | |
Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Shares excluded from the computation of diluted loss per share | 23,807 | 20,846 |
Prepaid Expenses (Narrative) (D
Prepaid Expenses (Narrative) (Details) - USD ($) $ in Millions | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Prepaid Expenses [Abstract] | ||
Consulting services | $ 0.2 | $ 0.1 |
Prepaid Expenses (Schedule Of P
Prepaid Expenses (Schedule Of Prepaid Expenses) (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Prepaid Expenses [Abstract] | ||
Prepaid services | $ 453 | $ 221 |
Prepaid bonds for German statutory costs | 136 | 188 |
Prepaid insurance | 44 | 62 |
Prepaid licenses, software tools and support | 11 | 17 |
Other prepaid expenses | 16 | 17 |
Prepaid expenses | $ 660 | $ 505 |
Intangible Assets (Details)
Intangible Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Intangible Assets [Abstract] | ||
Patents and copyrights | $ 15,184 | $ 16,612 |
Accumulated amortization | (12,858) | (13,734) |
Intangible assets | $ 2,326 | $ 2,878 |
Operating Lease Right-of-Use _2
Operating Lease Right-of-Use Assets (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2020USD ($) | |
Operating Lease Right-of-Use Assets [Abstract] | |
Impairment loss | $ 0.2 |
Debt (Narrative) (Details)
Debt (Narrative) (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 21 Months Ended | |||||
May 31, 2020USD ($) | Mar. 31, 2020USD ($) | Jan. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Sep. 30, 2020USD ($)item | Sep. 30, 2019USD ($) | Sep. 30, 2020USD ($)itemshares | Sep. 30, 2019USD ($) | Dec. 31, 2019USD ($) | Sep. 30, 2020USD ($)item | |
Debt Instrument [Line Items] | ||||||||||
Change in fair value of contingent payment obligations | $ (105,000) | $ (68,000) | $ (3,487,000) | $ 755,000 | ||||||
Unsecured Debt [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Change in fair value of contingent payment obligations | $ 400,000 | |||||||||
Convertible Debt [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate | 8.00% | 8.00% | 8.00% | |||||||
Interest expense | $ 220,000 | |||||||||
Amortization period | 5 years | |||||||||
Outstanding principal converted | $ 130,000 | |||||||||
Debt, term | 5 years | |||||||||
Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period One [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Measurement input | item | 0.25 | 0.25 | 0.25 | |||||||
Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Two [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Measurement input | item | 0.20 | 0.20 | 0.20 | |||||||
Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Three [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Measurement input | item | 0.15 | 0.15 | 0.15 | |||||||
Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Four [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Measurement input | item | 0.10 | 0.10 | 0.10 | |||||||
Note Payable To A Related Party [Member] | Secured Debt [Member] | Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate | 12.00% | 12.00% | 12.00% | |||||||
Repayments of Debt | $ 1,200,000 | |||||||||
Transfer of capital stock | 50.00% | |||||||||
Notes payable | $ 20,000 | $ 20,000 | $ 20,000 | |||||||
Unpaid fees and expenses | 3,100,000 | 3,100,000 | 3,100,000 | |||||||
Note Payable To A Related Party [Member] | Secured Debt [Member] | Mintz [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Unpaid fees and expenses | 3,600,000 | 3,600,000 | 3,600,000 | |||||||
Promissory Notes [Member] | Unsecured Debt [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Debt | $ 800,000 | $ 800,000 | $ 800,000 | |||||||
Interest rate | 4.00% | 4.00% | 4.00% | |||||||
Debt payment per month | $ 10,000 | |||||||||
Balloon payment date | Apr. 1, 2022 | |||||||||
Short Term Promissory Notes [Member] | Unsecured Debt [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate | 20.00% | 20.00% | 20.00% | |||||||
Proceeds from debt | $ 230,000 | |||||||||
Shares issued | shares | 1,740,426 | |||||||||
Convertible Debt, July 18, 2019 [Member] | Convertible Debt [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate | 7.50% | 7.50% | 7.50% | |||||||
Contingent Payment Obligation [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Litigation funds | $ 14,700,000 | $ 14,700,000 | $ 14,700,000 | |||||||
Contingent Payment Obligation [Member] | Unsecured Debt [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Proceeds from debt | 1,000,000 | |||||||||
Upfront payment | 5,000,000 | |||||||||
Paycheck Protection Program Loan [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest rate | 1.00% | |||||||||
Debt payment per month | $ 8,000 | |||||||||
Proceeds from debt | $ 200,000 | |||||||||
Letter Agreement [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Proceeds from debt | $ 600,000 | $ 400,000 | ||||||||
Contingent Payment Rights [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Common stock issued | 900,000 | 2,100,000 | ||||||||
Proceeds from debt | 1,000,000 | |||||||||
Change in fair value of contingent payment obligations | $ 400,000 | |||||||||
Debt, Investor Subscription Amount | 10,000,000 | |||||||||
Termination payment | 1,400,000 | 1,400,000 | 1,400,000 | |||||||
Contingent Payment Rights [Member] | Unsecured Debt [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Fair value of payment obligation | 3,000,000 | 3,000,000 | 3,000,000 | |||||||
Measurement input | 3,000,000 | 3,000,000 | 3,000,000 | |||||||
Contingent Payment Rights [Member] | Unsecured Debt [Member] | Termination Fee [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Fair value of payment obligation | 2,400,000 | 2,400,000 | 2,400,000 | |||||||
Measurement input | $ 2,400,000 | $ 2,400,000 | $ 2,400,000 | |||||||
Minimum [Member] | Contingent Payment Obligation [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Percentage of proceeds payment | 55.00% | |||||||||
Maximum [Member] | Contingent Payment Obligation [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Percentage of proceeds payment | 100.00% | |||||||||
Maximum [Member] | Contingent Payment Rights [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Debt, Proceeds Recovered | $ 10,000,000 |
Debt (Schedule Of Convertible N
Debt (Schedule Of Convertible Notes Payable) (Details) - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Dec. 31, 2019 | |
Debt Instrument [Line Items] | ||
Convertible notes, net | $ 3,010 | $ 2,733 |
Convertible Debt [Member] | ||
Debt Instrument [Line Items] | ||
Total principal balance | 3,890 | 3,565 |
Less Unamortized discount | 880 | 832 |
Convertible notes, net | $ 3,010 | 2,733 |
Amortization period | 5 years | |
Convertible Debt [Member] | Convertible Notes Dated September 10, 2018 [Member] | ||
Debt Instrument [Line Items] | ||
Fixed Conversion Rate | $ 0.40 | |
Effective Interest Rate | 23.40% | |
Maturity Date | Sep. 7, 2023 | |
Total principal balance | $ 600 | 700 |
Convertible Debt [Member] | Convertible Note Dated September 19, 2018 [Member] | ||
Debt Instrument [Line Items] | ||
Fixed Conversion Rate | $ 0.57 | |
Effective Interest Rate | 10.20% | |
Maturity Date | Sep. 19, 2023 | |
Total principal balance | $ 425 | 425 |
Convertible Debt [Member] | Convertible Notes Dated February/March 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Fixed Conversion Rate | $ 0.25 | |
Effective Interest Rate | 8.00% | |
Total principal balance | $ 1,300 | 1,300 |
Convertible Debt [Member] | Convertible Note Dated June/July 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Fixed Conversion Rate | $ 0.10 | |
Effective Interest Rate | 8.00% | |
Total principal balance | $ 365 | 390 |
Convertible Debt [Member] | Convertible Note Dated July 18, 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Fixed Conversion Rate | $ 0.08 | |
Effective Interest Rate | 46.10% | |
Maturity Date | Jul. 18, 2024 | |
Total principal balance | $ 700 | 700 |
Convertible Debt [Member] | Convertible Note Dated September 13, 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Fixed Conversion Rate | $ 0.10 | |
Effective Interest Rate | 25.90% | |
Maturity Date | Sep. 13, 2024 | |
Total principal balance | $ 50 | $ 50 |
Convertible Debt [Member] | Convertible Notes Dated January 8, 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Fixed Conversion Rate | $ 0.13 | |
Effective Interest Rate | 20.30% | |
Maturity Date | Jan. 8, 2025 | |
Total principal balance | $ 450 | |
Minimum [Member] | ||
Debt Instrument [Line Items] | ||
Effective Interest Rate | 8.00% | |
Minimum [Member] | Convertible Debt [Member] | Convertible Notes Dated February/March 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Maturity Date | Feb. 28, 2024 | |
Minimum [Member] | Convertible Debt [Member] | Convertible Note Dated June/July 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Maturity Date | Jun. 7, 2024 | |
Maximum [Member] | Convertible Debt [Member] | Convertible Notes Dated February/March 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Maturity Date | Mar. 13, 2024 | |
Maximum [Member] | Convertible Debt [Member] | Convertible Note Dated June/July 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Maturity Date | Jul. 15, 2024 |
Debt (Reconciliation Of Secured
Debt (Reconciliation Of Secured Contingent Obligation At Fair Value) (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | 21 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | Sep. 30, 2020 | |
Secured Debt [Abstract] | |||
Secured contingent payment obligation | $ 26,651 | ||
Secured contingent payment obligation | 28,788 | $ 26,651 | $ 28,788 |
Contingent Payment Obligation [Member] | Unsecured Debt [Member] | |||
Secured Debt [Abstract] | |||
Proceeds from contingent payment obligation | 1,000 | ||
Change in fair value | 1,350 | ||
Unsecured Debt [Abstract] | |||
Unsecured contingent payment obligation | |||
Reclassification of other liabilities | 1,003 | ||
Proceeds from sale of contingent payment rights | 984 | ||
Initial fair market value of modification | 436 | ||
Change in fair value | 1,350 | ||
Unsecured contingent payment obligation | 3,773 | 3,773 | |
Contingent Payment Obligation [Member] | Secured Debt [Member] | |||
Secured Debt [Abstract] | |||
Secured contingent payment obligation | 26,651 | 25,557 | 25,557 |
Change in fair value | 2,137 | 1,094 | |
Secured contingent payment obligation | 28,788 | 26,651 | $ 28,788 |
Unsecured Debt [Abstract] | |||
Change in fair value | $ 2,137 | $ 1,094 |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) - Secured Debt [Member] | Sep. 30, 2020item |
Measurement Input, Discount Rate [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Measurement input | 14.15 |
Measurement Input, Risk Free Interest Rate [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Measurement input | 0.15 |
Measurement Input, Entity Credit Risk [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Measurement input | 8 |
Measurement Input, Litigation Inherent Risk [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Measurement input | 6 |
Fair Value Measurements (Schedu
Fair Value Measurements (Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Secured Contingent Payment Obligation [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities | $ 28,788 | $ 26,651 |
Unsecured Contingent Payment Obligation [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities | 3,773 | |
Quoted Prices In Active Markets (Level 1) [Member] | Secured Contingent Payment Obligation [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities | ||
Quoted Prices In Active Markets (Level 1) [Member] | Unsecured Contingent Payment Obligation [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities | ||
Significant Other Observable Inputs (Level 2) [Member] | Secured Contingent Payment Obligation [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities | ||
Significant Other Observable Inputs (Level 2) [Member] | Unsecured Contingent Payment Obligation [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities | ||
Significant Unobservable Inputs (Level 3) [Member] | Secured Contingent Payment Obligation [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities | 28,788 | $ 26,651 |
Significant Unobservable Inputs (Level 3) [Member] | Unsecured Contingent Payment Obligation [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities | $ 3,773 |
Fair Value Measurements (Quanti
Fair Value Measurements (Quantitative Information) (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2020USD ($)item | |
Unsecured Debt [Member] | Minimum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated cash outflows | $ | $ 0 |
Duration | 1 year |
Unsecured Debt [Member] | Minimum [Member] | Estimated Probabilities [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated probabilities | item | 2 |
Unsecured Debt [Member] | Weighted Average [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated cash outflows | $ | $ 5.1 |
Duration | 2 years 4 months 24 days |
Unsecured Debt [Member] | Weighted Average [Member] | Estimated Probabilities [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated probabilities | item | 22 |
Unsecured Debt [Member] | Maximum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated cash outflows | $ | $ 8 |
Duration | 3 years |
Unsecured Debt [Member] | Maximum [Member] | Estimated Probabilities [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated probabilities | item | 38 |
Secured Debt [Member] | Minimum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated cash outflows | $ | $ 0 |
Duration | 1 year |
Secured Debt [Member] | Minimum [Member] | Estimated Probabilities [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated probabilities | item | 0 |
Secured Debt [Member] | Weighted Average [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated cash outflows | $ | $ 39.3 |
Duration | 2 years 4 months 24 days |
Secured Debt [Member] | Weighted Average [Member] | Estimated Probabilities [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated probabilities | item | 13 |
Secured Debt [Member] | Maximum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated cash outflows | $ | $ 58.5 |
Duration | 3 years |
Secured Debt [Member] | Maximum [Member] | Estimated Probabilities [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Estimated probabilities | item | 30 |
Legal Proceedings (Details)
Legal Proceedings (Details) $ in Thousands | 1 Months Ended | |||||||||||
Oct. 31, 2020USD ($)item | Sep. 30, 2020USD ($)item | Jul. 31, 2020item | Jun. 30, 2020item | May 31, 2020item | Apr. 30, 2020claim | Feb. 29, 2020item | Jul. 31, 2019item | Mar. 31, 2018item | Mar. 31, 2017item | Dec. 31, 2015item | Dec. 31, 2019USD ($) | |
Germany [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Accrued costs | $ | $ 240 | $ 370 | ||||||||||
ParkerVision v. Apple and Qualcomm (Middle District of Florida) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of petitions | 6 | |||||||||||
Number of patents allegedly infringed upon | 4 | 4 | ||||||||||
Number of patents dismissed | 3 | |||||||||||
Claim construction | 2 | |||||||||||
ParkerVision V. Intel (Western District of Texas) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of patents allegedly infringed upon | 2 | 8 | ||||||||||
ParkerVision v. TCL Technology Group Corp (Central District of California) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of patents allegedly infringed upon | 10 | |||||||||||
ParkerVision v. Intel II (Western District of Texas) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of patents allegedly infringed upon | 2 | |||||||||||
Number of patents found not infringed upon | 1 | |||||||||||
ParkerVision v. Qualcomm (Middle District of Florida) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of petitions | claim | 10 | |||||||||||
Number of patents allegedly infringed upon | 6 | |||||||||||
Number of patents found not infringed upon | 3 | |||||||||||
Number of patents found infringed upon | 2 | |||||||||||
Claim construction | claim | 7 | |||||||||||
ParkerVision v. Hisense (Western District of Texas) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of patents allegedly infringed upon | 10 | |||||||||||
Subsequent Event [Member] | ParkerVision v. Qualcomm (Middle District of Florida) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Estimated loss | $ | $ 1,300,000 | |||||||||||
Subsequent Event [Member] | ParkerVision v. TCL (Western District of Texas) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of patents allegedly infringed upon | 10 | |||||||||||
Subsequent Event [Member] | ParkerVision v. Buffalo (Western District of Texas) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of patents allegedly infringed upon | 10 | |||||||||||
Subsequent Event [Member] | ParkerVision v.Zyxel (Western District of Texas) [Member] | ||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||
Number of patents allegedly infringed upon | 10 |
Stock Issuance (Details)
Stock Issuance (Details) $ / shares in Units, $ in Thousands | Jun. 08, 2020USD ($)shares | Feb. 28, 2020USD ($)$ / sharesshares | Feb. 10, 2020USD ($)shares | Oct. 31, 2020USD ($)shares | Mar. 31, 2020USD ($)$ / sharesshares | Jan. 31, 2020USD ($)$ / sharesshares | Sep. 30, 2020USD ($)$ / sharesshares | Jul. 31, 2020USD ($)shares | Jun. 30, 2020USD ($) | Mar. 31, 2020USD ($)$ / shares | Sep. 30, 2019USD ($) | Jun. 30, 2019USD ($) | Sep. 30, 2020USD ($)$ / sharesitemshares | Sep. 30, 2019USD ($) | Mar. 16, 2020USD ($)$ / sharesshares |
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Outstanding warrants | shares | 13,900,000 | 13,900,000 | |||||||||||||
Sale of common stock | $ 230 | $ 768 | $ 2,850 | $ 180 | $ 60 | ||||||||||
Estimated fair market value | 2,000 | $ 2,000 | |||||||||||||
Proceeds from warrants exercised | 1,200 | ||||||||||||||
Change in fair value of contingent payment obligations | $ (105) | (68) | $ (3,487) | $ 755 | |||||||||||
Aspire Capital Fund, LLC [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
warrants exercised | shares | 1,070,000 | ||||||||||||||
Proceeds from warrants exercised | $ 380 | ||||||||||||||
Unsecured Debt [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Proceeds from sale of contingent payment rights | 1,000 | ||||||||||||||
Unsecured contingent payment obligation | 900 | ||||||||||||||
Change in fair value of contingent payment obligations | $ 400 | ||||||||||||||
Aspire Capital [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Warrants to purchase common stock | shares | 5,000,000 | ||||||||||||||
Exercise price per warrant | $ / shares | $ 0.74 | ||||||||||||||
Aspire Capital [Member] | Beneficial Owner [Member] | Aspire Capital Fund, LLC [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 9.99% | ||||||||||||||
Aspire Capital, Amendment [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Warrants to purchase common stock | shares | 5,000,000 | ||||||||||||||
Exercise price per warrant | $ / shares | $ 0.35 | ||||||||||||||
Consideration | $ / shares | $ 0.001 | ||||||||||||||
warrants exercised | shares | 1,430,000 | ||||||||||||||
Proceeds from warrants exercised | $ 500 | ||||||||||||||
Issuance of stock to consultants, shares | shares | 1,780,000 | ||||||||||||||
Common Stock [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Sale of common stock | $ 15 | $ 43 | $ 39 | $ 6 | |||||||||||
Issuance of stock to consultants, shares | shares | 30,000 | 50,000 | |||||||||||||
Issuance of stocks to consultants | $ 10 | $ 30 | |||||||||||||
Issuance of stocks to consultants, future shares | shares | 50,000 | ||||||||||||||
Maximum [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Number of successive three-month periods per agreement | item | 3 | ||||||||||||||
Maximum [Member] | Aspire Capital, Amendment [Member] | Beneficial Owner [Member] | Aspire Capital Fund, LLC [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 19.99% | ||||||||||||||
Weighted Average [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Warrant term | 3 years 3 months 18 days | 3 years 3 months 18 days | |||||||||||||
Exercise price per warrant | $ / shares | $ 0.44 | $ 0.44 | |||||||||||||
Subsequent Event [Member] | Common Stock [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Issuance of stock to consultants, shares | shares | 50,000 | ||||||||||||||
Issuance of stocks to consultants | $ 20 | ||||||||||||||
Private Placements With Accredited Investors [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Sale of common stock, number of shares | shares | 2,571,432 | ||||||||||||||
Sale of common stock | $ 900 | $ 200 | |||||||||||||
Sale of stock price per share | $ / shares | $ 0.35 | $ 0.35 | |||||||||||||
Private Placements With Accredited Investors B [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Sale of common stock, number of shares | shares | 1,169,232 | ||||||||||||||
Sale of stock price per share | $ / shares | $ 0.13 | ||||||||||||||
Private Placements With Accredited Investors C [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Sale of common stock, number of shares | shares | 166,667 | ||||||||||||||
Sale of stock price per share | $ / shares | $ 0.15 | ||||||||||||||
Chelsea Investor Relations [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Issuance of stock to consultants, shares | shares | 500,000 | ||||||||||||||
Issuance of stocks to consultants | $ 150 | ||||||||||||||
Agreement term | 24 months | ||||||||||||||
Tailwinds Research Group LLC [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Warrants to purchase common stock | shares | 200,000 | ||||||||||||||
Exercise price per warrant | $ / shares | $ 1 | ||||||||||||||
Estimated fair market value | $ 60 | ||||||||||||||
Agreement term | 12 months | ||||||||||||||
Securities Purchase Agreements [Member] | |||||||||||||||
Stock Authorization And Issuance [Line Items] | |||||||||||||||
Sale of common stock, number of shares | shares | 5,871,584 | ||||||||||||||
Sale of common stock | $ 2,100 | ||||||||||||||
Sale of stock price per share | $ / shares | $ 0.35 | $ 0.35 |
Share-Based Compensation (Narra
Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | Jun. 07, 2020 | Feb. 09, 2020 | Jan. 14, 2020 | Sep. 30, 2020 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Unrecognized compensation cost, net of estimated forfeitures | $ 600 | |||
Expected weighted average period to recognize the compensation cost, in years | 1 year | |||
Restricted Stock Units (RSUs) [Member] | 2019 Long-Term Incentive Equity Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Shares granted | 675,000 | |||
Restricted Stock Award [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Shares granted | 171,000 | |||
Settlement | $ 300 | |||
Expiration period | 5 years | |||
Restricted Stock Award [Member] | 2019 Long-Term Incentive Equity Plan [Member] | Share-based Payment Arrangement, Tranche One [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting Percentage | 50.00% | |||
Nonqualified Stock Options [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Options granted | 218,000 | |||
Options granted, exercise prices | $ 0.21 | |||
Expiration period | 5 years | |||
Nonqualified Stock Options [Member] | 2019 Long-Term Incentive Equity Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Options granted | 150,000 | |||
Options granted, exercise prices | $ 0.33 | |||
Nonqualified Stock Options [Member] | 2019 Long-Term Incentive Equity Plan [Member] | Share-based Payment Arrangement, Tranche One [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting Percentage | 50.00% | |||
Consultants [Member] | Restricted Stock Award [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Issuance of stock to consultants, shares | 20,000 | |||
Issuance of stocks to consultants | $ 10 | |||
Independent Directors [Member] | Restricted Stock Units (RSUs) [Member] | 2019 Long-Term Incentive Equity Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Options granted, exercise prices | $ 0.33 | |||
Shares granted | 150,000 | |||
Independent Directors [Member] | Restricted Stock Units (RSUs) [Member] | 2019 Long-Term Incentive Equity Plan [Member] | Share-based Payment Arrangement, Tranche One [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting Percentage | 50.00% | |||
Independent Directors [Member] | Nonqualified Stock Options [Member] | 2019 Long-Term Incentive Equity Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Options granted | 300,000 | |||
Options granted, exercise prices | $ 0.33 | |||
Independent Directors [Member] | Nonqualified Stock Options [Member] | 2019 Long-Term Incentive Equity Plan [Member] | Share-based Payment Arrangement, Tranche One [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting Percentage | 50.00% | |||
Robert Sterne [Member] | Stock Options [Member] | 2011 Long Term Incentive Equity Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Options granted | 100,000 | |||
Options granted, exercise prices | $ 0.33 | |||
Settlement | $ 100 |
Share-Based Compensation (Sched
Share-Based Compensation (Schedule Of Share-Based Compensation Expense Included In Statements Of Operations) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total share-based compensation expense | $ 240 | $ 286 | $ 1,004 | $ 401 |
Research And Development Expense [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total share-based compensation expense | 5 | |||
Selling, General and Administrative Expenses [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total share-based compensation expense | $ 240 | $ 286 | $ 1,004 | $ 396 |